Hilbe W - Search Results

1

Biomarkers of evasive resistance predict disease progression in cancer patients treated with antiangiogenic therapies.

Pircher A, Jöhrer K, Kocher F, Steiner N, Graziadei I, Heidegger I, Pichler R, Leonhartsberger N, Kremser C, Kern J, Untergasser G, Gunsilius E, Hilbe W. Pircher A, et al. Among authors: hilbe w. Oncotarget. 2016 Apr 12;7(15):20109-23. doi: 10.18632/oncotarget.7915. Oncotarget. 2016. PMID: 26956051 Free PMC article.

2

Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs).

Pircher A, Fiegl M, Untergasser G, Heidegger I, Medinger M, Kern J, Hilbe W. Pircher A, et al. Among authors: hilbe w. Lung Cancer. 2013 Aug;81(2):252-8. doi: 10.1016/j.lungcan.2013.04.014. Epub 2013 May 10. Lung Cancer. 2013. PMID: 23664449

3

Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality.

Pircher A, Wolf D, Heidenreich A, Hilbe W, Pichler R, Heidegger I. Pircher A, et al. Among authors: hilbe w. Int J Mol Sci. 2017 Oct 31;18(11):2291. doi: 10.3390/ijms18112291. Int J Mol Sci. 2017. PMID: 29088109 Free PMC article. Review.

4

Increased numbers of endothelial progenitor cells in peripheral blood and tumor specimens in non-small cell lung cancer: a methodological challenge and an ongoing debate on the clinical relevance.

Pircher A, Kähler CM, Skvortsov S, Dlaska M, Kawaguchi G, Schmid T, Gunsilius E, Hilbe W. Pircher A, et al. Among authors: hilbe w. Oncol Rep. 2008 Feb;19(2):345-52. Oncol Rep. 2008. PMID: 18202780

5

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.

Pircher A, Ploner F, Popper H, Hilbe W. Pircher A, et al. Among authors: hilbe w. Lung Cancer. 2010 Sep;69(3):265-71. doi: 10.1016/j.lungcan.2010.01.017. Epub 2010 Feb 18. Lung Cancer. 2010. PMID: 20167388 Review.

6

Cancer stem cells: characteristics and their potential role for new therapeutic strategies.

Bohl SR, Pircher A, Hilbe W. Bohl SR, et al. Among authors: hilbe w. Onkologie. 2011;34(5):269-74. doi: 10.1159/000327815. Epub 2011 Apr 26. Onkologie. 2011. PMID: 21577035 Review.

7

Biomarkers in tumor angiogenesis and anti-angiogenic therapy.

Pircher A, Hilbe W, Heidegger I, Drevs J, Tichelli A, Medinger M. Pircher A, et al. Among authors: hilbe w. Int J Mol Sci. 2011;12(10):7077-99. doi: 10.3390/ijms12107077. Epub 2011 Oct 21. Int J Mol Sci. 2011. PMID: 22072937 Free PMC article. Review.

8

New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules.

Pircher A, Wellbrock J, Fiedler W, Heidegger I, Gunsilius E, Hilbe W. Pircher A, et al. Among authors: hilbe w. Oncology. 2014;86(1):46-52. doi: 10.1159/000356871. Epub 2014 Jan 3. Oncology. 2014. PMID: 24401553 Review.

9

Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registry.

Kocher F, Hilbe W, Seeber A, Pircher A, Schmid T, Greil R, Auberger J, Nevinny-Stickel M, Sterlacci W, Tzankov A, Jamnig H, Kohler K, Zabernigg A, Frötscher J, Oberaigner W, Fiegl M. Kocher F, et al. Among authors: hilbe w. Lung Cancer. 2015 Feb;87(2):193-200. doi: 10.1016/j.lungcan.2014.12.006. Epub 2014 Dec 18. Lung Cancer. 2015. PMID: 25564398

10

Cardiovascular Comorbidities and Events in NSCLC: Often Underestimated but Worth Considering.

Kocher F, Fiegl M, Mian M, Hilbe W. Kocher F, et al. Among authors: hilbe w. Clin Lung Cancer. 2015 Jul;16(4):305-12. doi: 10.1016/j.cllc.2014.12.007. Epub 2014 Dec 30. Clin Lung Cancer. 2015. PMID: 25659438

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

128 results

Search Page